In the wake of the U.S. Supreme Court’s overturning of Roe v. Wade, there’s been a lot of focus on how it’s affecting the delivery of health care, but one area that hasn’t been as focused on is what this decision means for pre-natal testing and how labs and providers of tests need to be navigating this new landscape. In this episode of Clinical Lab Chat, Director of Business Intelligence Chris Wolski interviews Mitera Co-founder and CEO Saman Askari about the state of pre-natal testing and how at-home testing may be a bulwark in preserving reproductive rights and autonomy.